Clinical Trial Update: Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A [Phase 3]

View source ↗

Summary

Phase 3 study update reporting long-term safety and efficacy of efanesoctocog alfa (BIVV001) in previously treated patients with Hemophilia A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• efanesoctocog alfa (BIVV001) (efanesoctocog alfa)

Snippet

Sponsor: Bioverativ, a Sanofi company | Conditions: Hemophilia A | Phase 3 | Status: ACTIVE_NOT_RECRUITING